Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page
$ S$ @( b4 f P8 v" l) n
: c4 R$ { G8 U, `& {
" W* f* U) Y2 rSub-category:
: \# n+ ` {: P& t+ W1 y: N# ^Molecular Targets
3 x+ C# K* m# F
# F4 g5 m m1 x) T9 D
% j; F7 k. x' m) Y7 F. E0 ICategory:" c2 d& B i$ t) j9 H. [
Tumor Biology
" M. W, | A) O" k& [6 L7 w. R! k
& t% H- P5 W# l, TMeeting: y, V7 Y/ h1 `( ]- F# G: y0 w
2011 ASCO Annual Meeting 0 z- K7 c/ x" h5 b
1 N0 d' H U/ U! D/ R: X$ r, F" O' s6 ~9 ^! S' n* [: }* p1 g
Session Type and Session Title:
& F$ P5 F, w; M( c) N6 ]Poster Discussion Session, Tumor Biology
5 o' X) F, R$ y+ L; G/ ]
, m' f. ]* L, ?0 }2 b/ M9 T# K+ s' l2 B$ H
Abstract No:
8 r0 S1 i6 j8 p/ z' s, O10517
4 T2 [0 q. ~+ T, `6 d- V% a! M) m) r# v* p7 g8 k/ Z, _0 A) D
: k; O" V2 n6 Q
Citation:/ j6 @0 O, P* w3 R1 a% @
J Clin Oncol 29: 2011 (suppl; abstr 10517) 0 {9 Y D( C. `! [9 V5 O9 ~
8 {/ h/ u% p5 F$ k: {
7 r1 s0 U# J* d& ?Author(s):1 G r# K3 b5 G$ M( F; z: Z
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
1 d7 s/ ~- E: O7 M2 R+ O9 |5 o \- v8 H) K9 b0 I$ q. P! @) h
( n8 G2 r- T. D& F/ s
( q" ^$ L5 h' C* d9 v; fAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
+ G; i& j) |7 b9 w- x" V, |
$ W" ^& ]: B5 `; x9 v) \" B" J6 VAbstract Disclosures. U0 B5 {5 j2 L6 t
: T( M; R7 w7 i3 K4 r0 HAbstract:
2 d# N2 Y# ~; _+ ?2 w6 W; A/ v
& z% I# n. H- [. y$ n, j5 w) V. ]* \0 E7 D+ z6 u1 z
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.+ C+ _# w# F" h k# T0 h0 ?
! c4 G" h0 }5 y: f0 B
9 L. q; [4 g' s6 V3 [9 m5 y) F |
显身卡
